0 mV (at ؉60 mV: 2.07؎0.22 pA/pF in control versus 2.73؎0.22 pA/pF in Ang II, n‫;9؍‬ P<0.05). The increase in I NCX induced by Ang II was prevented by the treatment of the cells with the unspecific blocker of the ET receptors, TAK 044 (1 mol/L) (at ؉60 mV: 2.15؎0.27 pA/pF in control versus 2.01؎0.26 pA/pF in Ang II, n‫,5؍‬ NS). These results show, for the first time, that the effect of Ang II on I NCX is the result of the autocrine actions of ET released by the octapeptide. P revious experimental evidence indicates that some cardiovascular effects initially thought to be mediated by angiotensin II (Ang II) were, in fact, due to the release of endogenous endothelin (ET). In cultured neonatal rat cardiomyocytes, Ito et al 1 reported inhibition of Ang II-induced hypertrophy with a blocker of ET A receptors (BQ123) or antisense oligonucleotides directed against mRNA of pre-proET. In rats, the elevation of blood pressure induced by infusion of Ang II was reversed by the ET A blocker PD 155080. 2 The goal of the present study was to evaluate, in isolated myocytes, the effects of Ang II on the current produced by the NCX (I NCX ) working in the reverse mode and the possible autocrine role played by the release of ET in these actions. We present novel evidence that demonstrates, for the first time, that the reverse mode of the cardiac NCX is stimulated by endogenous ET released by the myocytes on Ang II regulation.
The goal of the present study was to evaluate the effects of Ang II on the current produced by the Na ؉ -Ca 2؉ exchanger (I NCX ) working in the reverse mode and the possible autocrine role played by the release of endothelin (ET) in these actions. I NCX was studied in isolation in cat cardiac myocytes. Angiotensin II (Ang II) (100 nmol/L) increased I NCX at potentials higher than 0 mV (at ؉60 mV: 2.07؎0.22 pA/pF in control versus 2.73؎0.22 pA/pF in Ang II, n‫;9؍‬ P<0.05). The increase in I NCX induced by Ang II was prevented by the treatment of the cells with the unspecific blocker of the ET receptors, TAK 044 (1 mol/L) (at ؉60 mV: 2.15؎0.27 pA/pF in control versus 2.01؎0.26 pA/pF in Ang II, n‫,5؍‬ NS). These results show, for the first time, that the effect of Ang II on I NCX is the result of the autocrine actions of ET released by the octapeptide. P revious experimental evidence indicates that some cardiovascular effects initially thought to be mediated by angiotensin II (Ang II) were, in fact, due to the release of endogenous endothelin (ET). In cultured neonatal rat cardiomyocytes, Ito et al 1 reported inhibition of Ang II-induced hypertrophy with a blocker of ET A receptors (BQ123) or antisense oligonucleotides directed against mRNA of pre-proET. In rats, the elevation of blood pressure induced by infusion of Ang II was reversed by the ET A blocker PD 155080. 2 The goal of the present study was to evaluate, in isolated myocytes, the effects of Ang II on the current produced by the NCX (I NCX ) working in the reverse mode and the possible autocrine role played by the release of ET in these actions. We present novel evidence that demonstrates, for the first time, that the reverse mode of the cardiac NCX is stimulated by endogenous ET released by the myocytes on Ang II regulation.
Materials and Methods
Cat cardiac myocytes were isolated according to the technique previously described. 3 Animals were provided by a local supplier (San Cayetano, Monte Grande, Argentina) and procedures were performed according to the Guide for the Care and Use of Laboratory Animals (US Department of Health and Human Services). The determination of the NCX current (I NCX ) was performed under the conditions previously described by Hobai and O'Rourke 4 with some modifications. In some experiments, L-type Ca 2ϩ current (I Ca ) was recorded. The composition of solutions and other details are described in an expanded Materials and Methods section that can be found in the online data supplement, available at http://www.circresaha.org.
Results and Discussion
Whereas the contribution of the reverse mode of the NCX to basal cardiac contraction is controversial, 5 increases in contractility due to stimulation of this mode of the NCX have been reported to be present after the effects of agonists such as Ang II 6 or ET. 7 Therefore, since the initial goal of the present study was the evaluation of the effects of Ang II on the reverse mode of the NCX, we measured I NCX under recording conditions that favor this mode over the forward mode. Figure 1 shows the inhibitory effects of the NCX blocker KB-R7943 (KBR, 10 mol/L) on whole-cell currents recorded under conditions of I NCX isolation. Note that KBR blocked both forward and reverse modes of NCX, as it was previously reported for this concentration of the agent. 8 Lower concentrations of KBR were proven to block selectively the reverse mode of NCX. 8 Consistently, no effects of this drug on the forward mode were observed when 5 mol/L KBR was used (shown in the online data supplement). Ni 2ϩ (10 mmol/L), another NCX antagonist, blocked the current registered at ϩ60 mV by 85Ϯ5% (nϭ11). On average, the apparent reversal potentials (E rev ) of I NCX were Ϫ44.4Ϯ2.5 mV (nϭ6) and Ϫ39.5Ϯ4.1 mV (nϭ11) estimated as the zero current potential of the KBR-and Ni 2ϩ -sensitive currents, respectively. These values are similar to the I NCX E rev values reported by other authors working in similar conditions to those of the present study. 4 The above experiments allowed us to conclude that the whole-cell currents registered were mainly underlain by the NCX (I NCX ).
Ballard and Schaffer 9 reported that Ang II or ET increased the activity of the NCX in canine cardiac sarcolemmal vesicles. Thus, we next examined whether Ang II was able to affect I NCX in isolated cat cardiac myocytes. Figure 2A depicts the time course of the effect of Ang II (100 nmol/L) on the current recorded at ϩ60 mV in a single myocyte. Ang II induced a gradual increase in the current that reaches steadystate values after 5 minutes of administration of the peptide. Average data of the current recorded at ϩ60 mV in the absence and presence of Ang II are shown in Figure 2C . This current increased by 24.7Ϯ4.9% (nϭ26) in the presence of Ang II. The Ang II type 1 receptor (AT 1 ) antagonist losartan (1 mol/L) reversed the effects of Ang II (data not shown).
The outward current recorded at ϩ60 mV is mostly but not totally I NCX because a small remnant current is present after the effects of the NCX blockers Ni 2ϩ or KBR. Thus, the possibility that the Ni 2ϩ -insensitive current could be affected by Ang II was evaluated. No increase in outward current was induced by Ang II (100 nmol/L) in the presence of Ni 2ϩ (10 mmol/L) (0.75Ϯ0.31 pA/pF in Ni 2ϩ and 0.78Ϯ0.36 pA/pF in Ni 2ϩ plus Ang II, nϭ5; NS), indicating that the current affected by Ang II is most likely I NCX . Moreover, to confirm that Ang II affects I NCX , we studied the effects of this peptide on the KBR-sensitive currents. Figure 2D shows average current density-voltage relations obtained in 9 myocytes exposed to 10 mol/L KBR after having obtained the increase in the whole-cell current by Ang II. Ang II induced a significant increase in outward currents at potentials positive to 0 mV. KBR blocked the currents recorded after Ang II to the same extent of those recorded in the absence of the peptide (Figure 1 ). Figure 1E shows the effects of Ang II on the average current-voltage relation for the KBR-sensitive currents, corresponding to I NCX , obtained by subtracting the currents in KBR to those recorded in both control and in Ang II. Ang II significantly increased I NCX at potentials positive to 0 mV. At ϩ60 mV, I NCX increased by 38.7Ϯ14.6% in the presence of Ang II (nϭ9).
We next examined whether the Ang II-induced increase in I NCX observed in the present study was produced by release of endogenous ET. For this purpose, we pretreated the cells with the nonselective blocker of ET receptors, TAK 044 (1 mol/L). This blocker did not affect basal current (at ϩ60 mV: 2.59Ϯ0.15 pA/pF in control versus 2.45Ϯ0.12 pA/pF in TAK 044-treated myocytes, nϭ13; NS). Figure 3A shows the time course of effects of Ang II in the presence of TAK 044 on the current registered at ϩ60 mV. In the presence of the ET receptor blocker, Ang II failed to induce enhancement of this current. On average, no effects of Ang II were observed in the presence of TAK 044 on the current recorded at ϩ60 mV ( Figure 3C) or at any of the tested voltages ( Figure 3D ). In addition, no effects of Ang II in the presence of TAK 044 were observed on the Ni 2ϩsensitive currents, representing I NCX (at ϩ60 mV: Figure 1 . Characterization of I NCX . A, Families of representative whole-cell currents evoked by depolarizing pulses between Ϫ80 to ϩ100 mV from a holding potential of Ϫ40 mV, recorded in a myocyte in the absence and presence of KBR (10 mol/L). Pulses (260 ms in duration) were delivered at 0.1 Hz. B, Voltage dependence of the average current density measured in 6 myocytes exposed to KBR (10 mol/L). C, Average current-voltage relations of the KBRsensitive currents, representing I NCX (nϭ6). To rule out the possibility that the ET receptor blocker TAK 044 is acting on the Ang II receptors, we performed experiments in which the L-type calcium current (I Ca ) was measured in the absence and presence of Ang II (100 nmol/L) with or without TAK 044 (1 mol/L) in the extracellular solution. We have recently reported that Ang II enhances I Ca via activation of AT 1 receptors in cat cardiac myocytes. 3 Under the recording conditions of the present study, the peak I Ca recorded at 0 mV increased by 23Ϯ8% (nϭ5) after 10 minutes in the presence of Ang II. A similar increment in I Ca after 10 minutes of Ang II was observed in the presence of TAK 044 (21Ϯ7%, nϭ5). These results suggest that this ET receptor blocker did not unspecifically bind to AT 1 receptors and that the endogenous ET released by Ang II did not affect I Ca . The previously reported failure of ET-1 to affect I Ca when standard whole-cell configuration is used can account for the last result. 10 Taken together, the above results allow us to suggest that in cardiac myocytes the stimulation of I NCX induced by Ang II is, in fact, mediated by endogenous ET released by Ang II. The major finding of this study is the demonstration at the cardiac single-cell level of the existence of an autocrine mechanism in the heart involving the myocyte as the source and target of ET. Additional observations and extended discussion of the results are presented in the online data supplement. 
